Plasma-derived medicines: Access and usage issues

Blood Transfusion

Volumn 10, Issue 3, 2012, Pages 273-278

  Farrugia, Albert ^a,b,d   Cassar, Josephine ^c,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b The Australian National University   (Australia)

^c UNIVERSITY OF CANBERRA   (Australia)

^d Almar Therapeutics Pty Ltd   (Australia)

Author keywords

Access; Evidence; Medicines; Plasma

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; ANTITHROMBIN III; ANTITOXIN; FIBRIN GLUE; FIBRINOGEN; IMMUNOGLOBULIN; PLASMA PROTEIN; PLASMA PROTEIN FRACTION; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 8;

BLEEDING; BLOOD BANK; BLOOD TRANSFUSION; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL EFFECTIVENESS; CRYOPRECIPITATE; EVIDENCE BASED MEDICINE; FRACTIONATION; GUILLAIN BARRE SYNDROME; HEMOPHILIA; HEMOPHILIA A; HUMAN; HUMORAL IMMUNE DEFICIENCY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOTHERAPY; MOTOR NEUROPATHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; REVIEW; SINGLE DRUG DOSE; VIRUS INACTIVATION; VIRUS TRANSMISSION;

ANIMALS; BLOOD COMPONENT TRANSFUSION; HUMANS; PLASMA;

EID: 84865166712     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2011.0118-11     Document Type: Review

References (42)

1. Good RA, Lorenz E. Historic aspects of intravenous immunoglobulin therapy. Cancer 1994; 68 (Suppl. 6): 1415-21.
2. Cohn EJ, Strong LE, Hughes WL, et al. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chemistry Soc 1946; 68: 459-75.
3. The blood program in World War II. Kendrick DB. Available at http://history.amedd.army.mil/booksdocs/wwii/blood/chapter12.htm. Accesed on 4 November 2011.
4. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ 1998; 317: 235-40.
5. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350: 2247-56. (Pubitemid 38669207)
6. Nilsson IM, Blomback M, Jorpes E, et al. Von Willebrand's disease and its correction with human plasma fraction 1-0. Acta Med Scand 1957; 159: 179-88.
7. Pool JG, Shannon AE. Production of high-potency concentrates of antihemophilic globulin in a closed-bag system. N Engl J Med 1965; 273: 1443-7.
8. Hershgold EJ, Pool JG, Pappenhagen AR. The potent antihemophilic globulin concentrate derived from a cold insoluble fraction of human plasma: characterization and further data on preparation and clinical trial. J Lab Clin Med 1966; 67: 23-32.
9. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984; 312: 326-30. (Pubitemid 15209308)
10. White GC II, McMillan CW, Kingdon HS, Shoemaker CB. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 1989; 320: 166-70. (Pubitemid 19033095)
11. Ettingshausen CE, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 2006; Suppl. 6: 102-6. (Pubitemid 44741510)
12. Good RA, Varco RL. A clinical and experimental study of agammaglobulinemia. Lancet 1955; 75: 245-71.
13. Pollack W, Gorman JG, Freda VJ, et al. Results of clinical trials of RhoGAM in women. Transfusion 1968; 8: 151-3.
14. Eibl MM. History of Immunoglobulin Replacement. Immunol Allergy Clin N Am 2008; 28: 737-64.
15. Hartung HP, Mouthon L, Ahmed R, et al. Clinical applications of intravenous immunoglobulins (IVIg)-beyond immunodeficiencies and neurology. Clin Exp Immunol 2009; 158 (Suppl 1): 23-33.
16. Roifman CM, Lederman HM, Lavi S, et al. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. Am J Med 1985; 79: 171-4. (Pubitemid 15246245)
17. Burnouf T. Plasma proteins: Unique biopharmaceuticals - unique economics. Pharmaceutical Policy & Law 2005-2006; 7: 209-18.
18. Farrugia A, Robert P. Plasma protein therapies: current and future perspectives. Best Pract Res Clin Haematol 2006; 19: 243-58. (Pubitemid 43118873)
19. Stonebraker JS, Amand RE, Bauman MV, et al. Modelling haemophilia epidemiology and treatment modalities to estimate the unconstrained factor VIII demand. Haemophilia 2004; 10: 18-26. (Pubitemid 38202136)
20. Stonebraker JS, Brooker M, Amand RE, et al. A study of reported factor VIII use around the world. Haemophilia 2010; 16: 33-46.
21. Miners AH, Sabin CA, Tolley KH, Lee CA. Costutility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics 2002; 20: 759-74. (Pubitemid 35034444)
22. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44. (Pubitemid 47236278)
23. Morado M, Villar A, Jimenez Yuste V, et al. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia 2005; 11: 79-83. (Pubitemid 40468053)
24. Eijkhout HW, van Der Meer JW, Kallenberg CG, et al. The effects of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multi center crossover trial. Ann Intern Med 2001; 135: 165-74. (Pubitemid 32738310)
25. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol 2010; 137: 21-30.
26. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008; 28: 779-802.
27. Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125: 1354-60.
28. Availability, safety and quality of blood products. World Health Assembly 21 May 2010. At http://apps. who.int/gb/ebwha/pdf-files/WHA63/A63-R12-en.pdf. Accessed on 30 September 2011.
29. Stonebraker JS, Amand RE, Nagle AJ. A country-by-country comparison of FVIII concentrate consumption and economic capacity for the global haemophilia community. Haemophilia 2003; 9: 245-50. (Pubitemid 36622024)
30. Kirpalani H, Whyte RK, Andersen C, et al. The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. J Pediatr 2006; 149: 301-7.
31. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362: 600-13.
32. Verghese SG. Elective fresh frozen plasma in the critically ill: what is the evidence? Crit Care Resusc 2008; 10: 264-8.
33. Evidence-based medicine. A new approach to teaching the practice of medicine. Evidence-Based Medicine Working Group. JAMA 1992; 268: 2420-5.
34. Criteria for the Clinical Use of Intravenous Immunoglobulin (IVIg) in Australia. Australian National Blood Authority. Available at http://www.nba.gov.au/ivig/pdf/criteria.pdf. Accessed on 4 November 2011.
35. Senn SJ. Falsificationism and clinical trials. Stat Med 1991; 10: 1679-92.
36. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev 2010; 7: CD007851.
37. Chapman KR, Stockley RA, Dawkins C, et al. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD 2009; 6: 177-84.
38. Farrugia A. Trialing plasma protein therapies for rare disorders: thinking outside the box. Pharmaceuticals Policy and Law 2009; 11: 345-52.
39. Goodman SN, Sladky JT. A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain-Barre. Clin Trials 2005; 2: 305-10. (Pubitemid 41306272)
40. Guideline On Clinical Trials In Small Populations. European Medicines Agency 2006. Available at http://www.emea.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003615.pdf Accessed on 4 November 2011.
41. The "Achilles" project: A WHO initiative to assure safety and availability of blood products in developing countries. Dr Ana Padilla, Blood Products & related Biologicals, Essential Medicines and Pharmaceutical Policies Department,World Health Organisation. Available at http://www.ipopi. org/uploads/media/PastEvents/presentations-november-2009/ 5%20WHO%20Achilles%20London4.pdf. Accessed on 4 November 2011.
42. Cheraghali AM, Aboofazeli R. Economical impact of plasma fractionation project in Iran on affordability of plasma-derived medicines. Transfus Med 2009; 19: 363-8.